Indefinite Delivery Contract SPE2DB24D9644

This IDC contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, provides a broad range of pharmaceutical products and medical supplies to support the recurring needs of military health facilities worldwide. The single-award, $499,999,999 indefinite delivery contract (IDC) under the SPE2DB program allows DLA to issue firm fixed-price delivery orders for a comprehensive portfolio of medications, including branded and generic prescription drugs, over-the-counter products, biologics, and medical consumables. This IDC complements DMS Pharmaceutical Group's existing prime vendor contracts for direct pharmaceutical distribution and pharmacy services to Department of Defense (DoD) sites. Through this contract, DMS Pharmaceutical Group supplies an extensive array of pharmaceutical items, such as flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications, to support the diverse medical requirements of military personnel and their dependents across DoD healthcare facilities. The contract has a period of performance through December 31, 2025, with no set-aside designation.